ClinicalTrials.gg
CompletedNCT06648824Updated Jan 28, 2025

Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants

A Phase 1 interventional study of Mitapivat and Midazolam in Healthy Participants, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the effect of mitapivat on the single oral dose pharmacokinetics (PK) of midazolam in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • AG-348
  • Mitapivat
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must not be pregnant or lactating.
  • Females of must agree to use .
  • between 18.0 and 32.0 kilogram per meter square (kg/m\^2), inclusive.
  • In good health, as determined by no findings from medical history, 12-lead (ECG) and vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the investigator or designee.
  • Able to comprehend and willing to sign the form (ICF) and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, ophthalmological (acute angle closure glaucoma), or psychiatric disorder, as determined by the investigator or designee.
  • History of significant , intolerance, or allergy to any relevant drug compound, food, or other substance (ie, allergy to study intervention or [microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry Blue II film-coat [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD\&C Blue #2]]).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (e.g., cholecystectomy). Uncomplicated appendectomy and hernia repair are allowed.
  • Significant acute, new-onset illness (e.g., flu, gastroenteritis) within 2 weeks prior to dosing.
  • Confirmed systolic blood pressure >150 or \<90 millimeters of mercury (mmHg), diastolic blood pressure >100 or \<50 mmHg, or pulse rate >100 or \<40 beats per minute (bpm). If any parameter falls outside of the specified range at screening or check-in, 2 repeat measurements will be performed and the participant will be excluded only if the mean of the parameter based on the 3 replicates falls outside of the specified range.
  • cardiac history or presence of findings, including any of the following:

    1. Heart rate \<40 bpm or >100 bpm
    2. Risk factors for torsades de pointes (e.g., heart failure, cardiomyopathy, or family history of long syndrome)
    3. Sick sinus syndrome, second- or third-degree atrioventricular block myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities
    4. QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 millisecond (msec) (healthy male participants) or >470 msec (healthy female participants); if QTcF is >450 msec (males) or >470 msec (females), 2 repeat measurements will be performed and the participant will be excluded only if the mean QTcF based on the 3 replicate ECGs is >450 msec (males) or >470 msec (females).
    5. QRS duration >110 msec, confirmed by manual overread; if value is >110 msec, 2 repeat measurements will be performed and the participant will be excluded only if the mean QRS duration based on the 3 replicate ECGs is >110 msec.
    6. PR interval \<120 or >220 msec, confirmed by manual overread; if value is \<120 or >220 msec, 2 repeat measurements will be performed and the participant will be excluded only if the mean PR interval based on the 3 replicate ECGs is \<120 or >220 msec.
    7. Repeated syncope or vasovagal episodes.
    8. Hypertension, angina, bradycardia (if assessed as clinically significant by the investigator) or severe peripheral arterial circulatory disorders
    9. History of autonomic dysfunction.
  • Positive hepatitis panel and/or positive test.
  • Administration of any vaccine within 30 days prior to dosing.
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Use or intend to use any prescription medications/products, other than non-hormonal , within 14 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Use or intend to use any slow-release medications/products considered to still be active within 14 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Use or intend to use any nonprescription medications/products including vitamins, minerals, high-dose biotin supplements and other supplements, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Participation in a clinical study involving administration of an medicinal product (new chemical entity) in the past 30 days or 5 half-lives of that drug (if known) prior to dosing, whichever is longer.
  • Has previously completed or withdrawn from this study or any other study investigating mitapivat and has previously received mitapivat.
  • Alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12-ounce (oz) (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  • Positive urine drug screen at screening; positive alcohol test result or positive urine drug screen at check-in.
  • History of alcoholism or drug/chemical abuse within 2 years prior to check-in.
  • Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in. Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to check-in and not willing to refrain from consumption of these foods or beverages throughout the study until end of study.
  • Consumption of caffeine- or xanthine-containing products within 48 hours prior to check-in and not willing to refrain from consumption of these products while at the study site.
  • Consumption of vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and mustard greens), or charbroiled meat within 7 days prior to dosing and not willing to refrain from consumption of these foods until end of study.
  • Receipt of blood products within 2 months prior to check-in.
  • Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening.
  • Poor peripheral venous access.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Mitapivat and Midazolam

    Participants will receive single oral dose of 2 milligram (mg) midazolam on Day 1 followed by 100 mg mitapivat, orally, twice daily (BID) from Day 3 to 13. On Day 14, participants will receive single oral dose of 2 mg midazolam and 100 mg mitapivat orally, BID. Midazolam will be co-administered with morning mitapivat dose.

    Drug: Mitapivat · Drug: Midazolam

Interventions

  • Oral tablets

    Also known as: AG-348, PYRUKYND®, AG-348 sulfate hydrate, Mitapivat sulfate

  • Oral syrup

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve Extrapolated From Time Zero to Infinity (AUC0-infinity) of Midazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) of Midazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  3. Maximum Observed Plasma Concentration (Cmax) of Midazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to 12 Hours Post-dose (AUC0-12) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  2. Maximum Observed Plasma Concentration (Cmax) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  3. Area Under the Plasma Concentration-Time Curve Over a Dosing Interval (Tau) at Steady State (AUC0-tau,ss) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  4. Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  5. Time to Last Measurable Concentration (tlast) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  6. Time to Reach Maximum Concentration (tmax) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  7. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-infinity) of 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  8. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) of 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  9. Maximum Observed Plasma Concentration (Cmax) of 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  10. Metabolite-to-Parent Ratio of Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-infinity) for Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  11. Metabolite-to-Parent Ratios of Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) for Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  12. Metabolite-to-Parent Ratio of Maximum Observed Plasma Concentration (Cmax) for Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  13. Percentage of Area Under the Concentration-Time Curve Due to Extrapolation From the Last Quantifiable Concentration to Infinity (AUC%extrap) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  14. Time to Last Measurable Concentration (tlast) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  15. Time to Reach Maximum Concentration (tmax) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  16. Terminal Elimination Half-Life (t1/2) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  17. Apparent Total Body Clearance (CL/F) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  18. Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Midazolam and 1'-hydroxymidazolam

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 14

  19. Number of Participants With Adverse Events (AEs), AEs by Severity, and Relatedness to Study Treatment

    Time frame: Up to Day 24

  20. Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Assessments

    Time frame: Baseline up to Day 24

  21. Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Baseline up to Day 14

  22. Number of Participants With Clinically Significant Change From Baseline in Vital Signs Parameters

    Time frame: Baseline up to Day 24

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Oct 17, 2024
Primary completionActual
Dec 3, 2024
CompletionActual
Dec 3, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648824
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Oct 17, 2024
Primary completion
Dec 3, 2024
Completion
Dec 3, 2024
Last update
Jan 28, 2025

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mitapivat · Midazolam

Start the discussion